Context Therapeutics Inc Dossier - Source-backed chat

Context Therapeutics Inc

CNTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.49

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.31Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $28.9M

Enterprise Value −$14.1M

Shares Outstanding 95.2M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Context Therapeutics is a highly promising, clinical-stage biopharmaceutical company specializing in the development of next-generation T cell engaging (TCE) bispecific antibodies for solid tumors. The company's lead asset, CTIM-76 (a selective CLDN6 x CD3 bispecific), recently demonstrated strong proof-of-concept in June 2026 with a 29% confirmed ORR and 57% DCR in heavily pretreated, late-line platinum-resistant ovarian cancer patients. Backed by a robust cash runway extending into mid-2027, a fully bought-out royalty-free asset in CT-202, and an upcoming clinical catalyst for CT-95 in September 2026, Context is well-positioned to capture significant long-term value in the oncology space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$4.25

High · most bullish analyst$6.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is characterized by clinical or safety setbacks. CTIM-76's transition to Q3W dosing or higher dose cohorts triggers severe, unexpected toxicities (such as high-grade CRS or neurotoxicity), halting the trial. CT-95's September 2026 data fails to show meaningful anti-tumor activity, or the mesothelin 'sink' limits therapeutic exposure. CT-202 trial initiation is delayed in Australia, and rapid cash burn forces a highly dilutive equity financing round under unfavorable market conditions.

Base CaseCentral scenario

The base case assumes successful execution of the clinical pipeline. CTIM-76 successfully transitions to a Q3W dosing schedule in 2H 2026, paving the way for Phase 1b expansion in 2027. CT-95 delivers positive interim Phase 1a safety and efficacy data in September 2026, and CT-202 initiates its Phase 1 trial on schedule in Q3 2026. The company maintains disciplined spending, keeping its cash runway intact into mid-2027, and secures additional non-dilutive or strategic financing to support late-stage development.

Bull CaseUpside scenario

Successful clinical development and potential commercialization of CTIM-76 and CT-202, leveraging favorable safety profiles (low-grade CRS) and full economic rights to capture significant market share in solid tumors.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong clinical proof-of-concept for lead asset CTIM-76, showing a 29% confirmed ORR in heavily pretreated platinum-resistant ovarian cancer patients.
Favorable safety profile for CTIM-76 with low-grade, manageable adverse events and cytokine release syndrome limited to Grade 1 (11% at active doses).
Full economic ownership of CT-202 secured via a license amendment with BioAtla, eliminating all future milestone and royalty obligations.
Robust cash position of $54.5 million as of March 31, 2026, providing a clear runway into mid-2027 to reach multiple clinical milestones.

Key Investment Risks

Early-stage clinical development risk, as all pipeline assets are currently in Phase 1 trials and subject to high attrition rates.
Potential for severe toxicities, such as cytokine release syndrome (CRS), which is a class-wide risk for T cell engaging bispecific antibodies.
Financing risk, as the company is pre-commercial and will require substantial additional capital to fund late-stage clinical trials beyond mid-2027.
Intense competition in the solid tumor bispecific and antibody-drug conjugate (ADC) landscape.

Thesis Invalidation Triggers

Failure of CTIM-76 to maintain safety or efficacy during the Q3W dosing evaluation or Phase 1b expansion.
Negative or inconclusive interim Phase 1a data for CT-95 in September 2026, indicating lack of efficacy or poor pharmacokinetics.
Significant delays in dosing the first patient for the CT-202 Phase 1 trial in Q3 2026.
Unexpected acceleration of cash burn that shortens the operational runway to early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.